BR112020025380A2 - composições de terlipressina e seus usos - Google Patents

composições de terlipressina e seus usos Download PDF

Info

Publication number
BR112020025380A2
BR112020025380A2 BR112020025380-4A BR112020025380A BR112020025380A2 BR 112020025380 A2 BR112020025380 A2 BR 112020025380A2 BR 112020025380 A BR112020025380 A BR 112020025380A BR 112020025380 A2 BR112020025380 A2 BR 112020025380A2
Authority
BR
Brazil
Prior art keywords
terlipressin
acetate
amount
concentration
pharmaceutical composition
Prior art date
Application number
BR112020025380-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Mattias Malm
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of BR112020025380A2 publication Critical patent/BR112020025380A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BR112020025380-4A 2018-06-15 2019-06-14 composições de terlipressina e seus usos BR112020025380A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862685447P 2018-06-15 2018-06-15
US62/685,447 2018-06-15
PCT/IB2019/055004 WO2019239386A1 (en) 2018-06-15 2019-06-14 Terlipressin compositions and uses thereof

Publications (1)

Publication Number Publication Date
BR112020025380A2 true BR112020025380A2 (pt) 2021-05-18

Family

ID=67742882

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020025380-4A BR112020025380A2 (pt) 2018-06-15 2019-06-14 composições de terlipressina e seus usos

Country Status (9)

Country Link
US (1) US11931398B2 (https=)
EP (1) EP3806823A1 (https=)
JP (2) JP7523775B2 (https=)
CN (1) CN112969449B (https=)
BR (1) BR112020025380A2 (https=)
CA (1) CA3103215A1 (https=)
MX (1) MX2020013389A (https=)
TW (1) TW202003548A (https=)
WO (1) WO2019239386A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220080023A1 (en) * 2018-12-21 2022-03-17 Arecor Limited Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형
CN114177147B (zh) * 2021-12-15 2023-05-23 福建省闽东力捷迅药业股份有限公司 一种注射用特利加压素的制备方法以及制得的注射用特利加压素
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
CN1244794A (zh) * 1997-11-06 2000-02-16 奥尔班公司 用于药物释放的稳定的干燥药物组合物及其制备方法
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
CN102068685A (zh) * 2010-04-09 2011-05-25 深圳翰宇药业股份有限公司 一种特利加压素制剂及其制备方法
CN102440957B (zh) 2011-12-16 2013-09-25 深圳市健元医药科技有限公司 醋酸特利加压素鼻腔喷雾剂及其制备方法
CN104334117A (zh) 2012-01-26 2015-02-04 恩多沙普公司 用远端和/或近端控制来输送管腔闭塞装置的系统、装置和方法
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
CN105592855A (zh) * 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CN106188218B (zh) * 2016-07-14 2018-11-23 江苏诺泰澳赛诺生物制药股份有限公司 一种提高多肽原料药稳定性的方法
GB201721846D0 (en) 2017-12-22 2018-02-07 Arecor Ltd Novel composition
KR20220011697A (ko) 2019-05-22 2022-01-28 바이오비에 아이앤씨. 테를리프레신 제형

Also Published As

Publication number Publication date
US20210161995A1 (en) 2021-06-03
JP2024086898A (ja) 2024-06-28
US11931398B2 (en) 2024-03-19
CN112969449B (zh) 2025-03-11
MX2020013389A (es) 2021-03-31
CN112969449A (zh) 2021-06-15
JP7523775B2 (ja) 2024-07-29
EP3806823A1 (en) 2021-04-21
WO2019239386A1 (en) 2019-12-19
JP2021527084A (ja) 2021-10-11
TW202003548A (zh) 2020-01-16
CA3103215A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
BR112020025380A2 (pt) composições de terlipressina e seus usos
Liao et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats Corrigendum in/10.3892/etm. 2025.12953
Roberts et al. The clinical relevance of plasma protein binding changes
ES2942132T3 (es) Efecto protector de DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG y LYSOPC frente a fármacos que provocan canalopatías
ES2733639T3 (es) Composiciones de insulina de acción rápida
ES2781551T3 (es) Moduladores de la actividad del complemento
BR112020002804A2 (pt) composição farmacêutica líquida, e, kit
DK2525796T3 (en) An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease
ES2953005T3 (es) Tratamiento para el cáncer
TWI635874B (zh) 艾妥鈣塞(etelcalcetide)(amg 416)之穩定液體調配物
Saarikoski et al. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol
BR112017006112B1 (pt) Formulação de proteína de fusão recombinante
KR102938473B1 (ko) 항체 함유 제제
BR112020001101A2 (pt) composição farmacêutica do complexo de proteína il-15 e usos da mesma
BR112021007083A2 (pt) tratamento de doença neurológica com zilucoplan
Shabalin et al. Molecular determinants of vascular transport of dexamethasone in COVID-19 therapy
Quagliata et al. Therapeutic applications of thymosin peptides: a patent landscape 2018-present
ES3027617T3 (en) Liquid pharmaceutical composition
TW201440783A (zh) 含有米卡芬淨或其鹽的醫藥組成物
Karunaratne et al. Interaction between preservatives and a monoclonal antibody in support of multidose formulation development
Zhong et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer
RU2497520C1 (ru) Способ коррекции нарушений функциональной активности тромбоцитов
Frost et al. Findings of the neuromuscular blocking agent rocuronium in blood from deceased subjects several months after exposure: A report of two cases
Swart et al. Safety, tolerability and toxicokinetics of the novel mitochondrial drug SUL-138 administered orally to rat and minipig
CN114392352A (zh) 一种稳定的抗pd-1抗体的药物制剂

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]